颅内注射表达MGMT的γδ T细胞治疗初诊胶质母细胞瘤
本研究在23例初诊胶质母细胞瘤患者中,经Rickham导管向切除腔注射表达MGMT的γδ T细胞(DRI),联合替莫唑胺治疗,13例可评估。未观察到剂量限制性毒性、细胞因子释放综合征或神经毒性;所有患者中位无进展生存期9.9个月,中位总生存期15.6个月。
要点
- 颅内注射DRI γδ T细胞联合替莫唑胺耐受良好,无剂量限制性毒性。
- 所有治疗患者中位无进展生存期9.9个月,中位总生存期15.6个月。
- 重复给药队列中位无进展生存期达16.1个月。
核心结论
- 颅内注射表达MGMT的γδ T细胞联合替莫唑胺在初诊胶质母细胞瘤中耐受良好,并显示出持续令人鼓舞的疗效趋势。
研究设计与样本
- 单臂研究,共入组23例初诊胶质母细胞瘤患者,其中13例接受治疗;62%为男性,中位年龄66岁(范围21-75岁),92%为IDH野生型,54%为MGMT非甲基化,46%为次全切除。
- 队列1、2、3分别接受1、3或最多6剂DRI细胞(每剂1×10^7),经置于切除腔的Rickham导管给药,联合每个维持周期第1天静脉替莫唑胺150 mg/m2每日一次,随后4天口服替莫唑胺。
主要发现
- 未观察到剂量限制性毒性,也未发生细胞因子释放综合征或免疫效应细胞相关神经毒性综合征。
- 接受DRI γδ T细胞治疗患者的中位随访时间为15.6个月。
- 队列1单次给药患者的中位无进展生存期为8.0个月;所有患者的中位无进展生存期为9.9个月;队列2和3重复给药患者的中位无进展生存期为16.1个月。
- 所有患者的中位总生存期为15.6个月。
临床怎么用
- 对于初诊胶质母细胞瘤,可考虑颅内注射表达MGMT的γδ T细胞联合替莫唑胺作为研究性治疗选项,需在临床试验框架下进行。
局限性
- 样本量小,仅13例接受治疗,且为非随机设计,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We developed a novel approach to treat newly diagnosed glioblastoma (GBM) using genetically modified gamma-delta (γδ) T cells following the forced upregulation of stress-associated targets on tumor cells. We leveraged the temozolomide (TMZ)-induced activation of the DNA damage response pathway to transiently upregulate the natural killer ligand (NKG2D-L) targets on GBM. Manufactured γδ T cells are engineered to be resistant to alkylating chemotherapies, including TMZ, through insertion of a methylguanine-DNA methyltransferase (MGMT)-expressing lentivector (DeltEx drug-resistant immunotherapy-DRI). METHODS: A total of 23 patients were enrolled, and 13 were treated (62% male; median age 66 years [range, 21-75]; 92% isocitrate dehydrogenase wild type (IDH-WT), 54% MGMT unmethylated, 46% subtotal resection). Cohorts 1, 2, and 3 received 1, 3, or up to 6 doses, respectively (1 × 107 DRI cells/dose), using a Rickham catheter, which was placed into the resection cavity. The DRI cells were dosed in combination with 150 mg/m2 intravenous (IV) TMZ once per day on Day (D) 1 of each maintenance cycle, which was followed by 4 days of oral TMZ. RESULTS: No dose-limiting toxicities were seen nor were any occurrences of cytokine release syndrome (CRS) or neurotoxicity (immune effector cell-associated neurotoxicity syndrome) observed. The median follow-up of patients who received DRI γδ T cells was 15.6 months. For Cohort 1 patients who received a single dose of DRI γδ T cells, the median progression-free survival (mPFS) was 8.0 months; the median PFS was 9.9 months for all patients and 16.1 months for patients who received repeated doses in Cohorts 2 and 3. The median overall survival for all patients was 15.6 months. CONCLUSION: To date, all patients had manageable toxicity with outpatient treatment and a continued encouraging trend in outcomes from repeated investigational treatments with intracranially delivered, longitudinal DRI γδ T cells.
引用
- Nabors LB, Lobbous M, Han X, et al. Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma. J Clin Oncol. 2026. PMID: 42418736. doi:10.1200/JCO-25-02463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。